MBX Biosciences, Inc. (MBX) stock
MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$55.94+1.43 (+2.62%)
Close on Nov 13, 2026Market cap $2.69BP/E –Yield –
MBX Biosciences cash
Cash and short-term investments held at the end of each period.
MBX Biosciences's cash was $481.60M at Sep 30, 2026. For fiscal 2025 it was $373.70M, up 42.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $373.70M | +42.6% |
| FY2024 | Dec 31, 2024 | $262.10M | +224.9% |
| FY2023 | Dec 31, 2023 | $80.68M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $481.60M | +23.0% |
| Q2 FY2026 | Jun 30, 2026 | $418.60M | +86.1% |
| Q1 FY2026 | Mar 31, 2026 | $440.00M | +82.7% |
| Q4 FY2025 | Dec 31, 2025 | $373.70M | +42.6% |
| Q3 FY2025 | Sep 30, 2025 | $391.70M | +41.4% |
| Q2 FY2025 | Jun 30, 2025 | $224.90M | +178.8% |
| Q1 FY2025 | Mar 31, 2025 | $240.80M | – |
| Q4 FY2024 | Dec 31, 2024 | $262.10M | – |
| Q3 FY2024 | Sep 30, 2024 | $277.10M | – |
| Q4 FY2023 | Dec 31, 2023 | $80.68M | – |
See a number that looks wrong?